Abstract:Abstract The majority of p53 missense mutations identified in cancer patients are in the DNA-binding domain and are characterized as either structural or contact mutations. These missense mutations exhibit inhibitory effects on wild-type p53 activity. More importantly, these mutations also demonstrate gain-of-function (GOF) activities characterized by increased metastasis, poor prognosis, and drug resistance. To better understand the activities by which TP53 mutations, identified in Li-Fraumeni syndrome, contribute to tumorigenesis in vivo, we generated a novel germline p53R245W allele (contact mutation) and compared it to existing p53R172H (structural mutation) and p53R270H (contact mutation) alleles. Thymocytes from heterozygous mice showed all three hot-spot mutations exhibited similar inhibitory effects on wild type p53 transcription in vivo and tumors from these mice had similar levels of loss of heterozygosity. However, the overall survival of p53R245W/+ and p53R270H/+ mice, but not p53R172H/+ mice, was significantly shorter than that of p53+/- mice, demonstrating p53 mutation-specific GOF contributions to tumor development. Furthermore, p53R245W/+ and p53R270H/+ mice had more osteosarcoma metastases than p53R172H/+ mice, indicating that these two contact mutants have stronger GOF in driving osteosarcoma metastasis. Omics analyses using RNA-sequencing data from p53R172H/+, p53R245W/+, and p53R270H/+ primary osteosarcomas in comparison to p53+/- indicated GOF was mediated by distinct pathways among the three mutations. Thus, both the inhibitory effect of mutant over WT p53, and GOF activities of mutant p53 contributed to tumorigenesis in vivo. Targeting p53 mutant-specific pathways may be important for therapeutic outcomes in osteosarcomas. Citation Format: Shunbin Xiong, Dhruv Chachad, Yun Zhang, Jovanka Gencel-Augusto, Mario Sirito, Vinod Pant, Peirong Yang, Chang Sun, Guillermina Lozano. Differences in gain-of-function and inhibitory effects amongst p53 mutants in vivo [abstract]. In: Proceedings of the AACR Special Conference: Cancer Metastasis; 2022 Nov 14-17; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;83(2 Suppl_2):Abstract nr A042.

Oncogenic and teratogenic effects of p53Y217C, a mouse model of the human hotspot mutant p53Y220C

Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome

High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene

Effects of genetic background on tumorigenesis in p53-deficient mice

p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator

Differential Gain-of-Function Activity of Three P53 Hotspot Mutants in Vivo

Dominant-negative but Not Gain-of-function Effects of a P53.r270h Mutation in Mouse Epithelium Tissue after DNA Damage.

Functional Diversity of P53 in Human and Wild Animals

The gain of function of p53 cancer mutant in promoting mammary tumorigenesis

Generation and Characterization of P53 Mutant Mice.

p53 mutant mice that display early ageing-associated phenotypes

The Trp53 Delta Proline (trp53δp) Mouse Exhibits Increased Genome Instability and Susceptibility to Radiation-Induced, but Not Spontaneous, Tumor Development.

P53 Gain-of-function Cancer Mutants Induce Genetic Instability by Inactivating ATM

Gain of Function of P53 Cancer Mutants in Disrupting Critical DNA Damage Response Pathways

Network effect of Wt-mutant p53 interactions and implications on p53 gene therapy.

P53 Gain-of-Function: Tumor Biology and Bioinformatics Come Together

Chromosome Stability, in the Absence of Apoptosis, is Critical for Suppression of Tumorigenesis in Trp53 Mutant Mice

Differences in gainof-function and inhibitory effects amongst p53 mutants in vivo

Alterations Of The P53 Tumor-Suppressor Gene In Transformed Mouse-Liver Cells

Abstract A042: Differences in Gain-of-function and Inhibitory Effects Amongst P53 Mutants in Vivo

Aging-associated truncated form of p53 interacts with wild-type p53 and alters p53 stability, localization, and activity.